The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
A-Alpha Bio
Measures and models protein-protein interactions at scale using synthetic biology.
What they do
A-Alpha Bio uses synthetic biology and next-generation sequencing to characterize millions of physical protein-protein interactions simultaneously. Biopharmaceutical companies utilize this quantitative data to train predictive machine learning models, accelerating the discovery of antibody therapeutics and molecular glues.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Protein design
- Product type
- Service
- Stage
- Series A
- Headquarters
- Seattle, USA
- Region
- North America
- Founded
- 2017
- Total funding
- $22M raised
Notable investors: Madrona Venture Group, Xora Innovation, Cercano Management.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
Closing the Assay Loop: Inside Anthropic's $400M Wet Lab Pivot
Dr. Dereck Mush, MD, MBA
Bypassing Carrier Suppression: The 31-Valent Conjugate Architecture Reshaping Pneumococcal Vaccinology
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA